UK markets open in 7 hours 32 minutes

Pfizer Inc. (0Q1N.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
50.83+0.25 (+0.49%)
At close: 07:12PM BST
Full screen
Previous close50.58
Open50.82
BidN/A x N/A
AskN/A x N/A
Day's range50.26 - 50.82
52-week range50.26 - 50.82
Volume247,152
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)0.65
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial

    NEW YORK, October 04, 2022--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide) compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. The study met its primary endpoint with a statistically significant and clinica

  • Business Wire

    Pfizer Completes Acquisition of Biohaven Pharmaceuticals

    NEW YORK, October 03, 2022--Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.

  • Business Wire

    Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

    NEW YORK & MAINZ, Germany, September 26, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age. The request for Emergency Use Authorization of the Omicron BA.4/BA.5-adapted bivalent vaccine in this age group is sup